RESÚMENES ABRIL 2008

.

Addictive Disorders

(Haga un click en la información del journal para acceder al resúmen)

5 – doble-ciego o metanálisis; 4 – subanálisis o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión

GRATIS = Texto gratuito en algunos países de la región iberoamericana (algunos artículos requieren ir a la tabla de contenidos del número actual de la revista)

 

GRATIS 3 - Screening, diagnosis and referral for substance use disorders

Michigan Quality Improvement Consortium. 2007 Aug. 1 p

 

GRATIS 3! - Cocaine and Opioid Use During Pregnancy: Prevalence and Management

Chaya G. Bhuvaneswar, Grace Chang, Lucy A. Epstein, and Theodore A. Stern

Prim Care Companion J Clin Psychiatry. 2008; 10(1): 59–65

 

GRATIS 3! - Bridging the Clinical Gap: Managing Patients with Co-occurring Mood, Anxiety, and Alcohol Use Disorders

Alan F. Schatzberg, Roger D. Weiss, Kathleen T. Brady, and Larry Culpepper

Primary Psychiatry. 2008;15:4(suppl 3):1-16

 

GRATIS 3 - Review: executive functioning and cannabis use

ALMEIDA, Priscila Previato, NOVAES, Maria Alice Fontes Pinto, BRESSAN, Rodrigo Affonseca et al.

Rev. Bras. Psiquiatr., Mar. 2008, vol.30, no.1, p.69-76

 

3 - Association of Low Striatal Dopamine D2 Receptor Availability With Nicotine Dependence Similar to That Seen With Other Drugs of Abuse

Christoph Fehr, Igor Yakushev, Nina Hohmann, Hans-Georg Buchholz, Christian Landvogt, Hanna Deckers, Alexandra Eberhardt, Marie Kläger, Michael N. Smolka, Armin Scheurich, Thomas Dielentheis, Lutz G. Schmidt, Frank Rösch, Peter Bartenstein, Gerhard Gründer, and Mathias Schreckenberger

Am J Psychiatry 2008; 165:507-514

5 - Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study

Hidehiko Takahashi, Yota Fujimura, Mika Hayashi, Harumasa Takano, Motoichiro Kato, Yoshiro Okubo, Iwao Kanno, Hiroshi Ito and Tetsuya Suhara

The International Journal of Neuropsychopharmacology (2008), 11:413-417

 

3 - New treatments for cocaine dependence: a focused review

Laurent Karila, David Gorelick, Aviv Weinstein, Florence Noble, Amine Benyamina, Sarah Coscas, Lisa Blecha, William Lowenstein, Jean Luc Martinot, Michel Reynaud and Jean Pierre Lépine

The International Journal of Neuropsychopharmacology (2008), 11:425-438

 

3 - Neuroendocrine pathways in benzodiazepine dependence: new targets for research and therapy

Annemarie Heberlein, Stefan Bleich, Johannes Kornhuber, Thomas Hillemacher

Human Psychopharmacology: Clinical and Experimental. Volume 23, Issue 3, Pages 171 - 181

 

3 - Opioid dependence and pregnancy

Winklbaur, Bernadette; Jung, Erika; Fischer, Gabriele

Current Opinion in Psychiatry. 21(3):255-259, May 2008

3 - Identifying Methamphetamine Users at Risk for Major Depressive Disorder: Findings from the Methamphetamine Treatment Project at Three-Year Follow-Up

Suzette Glasner-Edwards;  Larissa J. Mooney;  Patricia Marinelli-Casey;  Maureen Hillhouse;  Alfonso Ang;  Richard Rawson; the Methamphetamine Treatment Project Corporate Authors

American Journal on Addictions, Volume 17, Issue 2 March 2008, pages 99 - 102

 

3 - Long-Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2-5 Years

David A. Fiellin;  Brent A. Moore;  Lynn E. Sullivan;  William C. Becker;  Michael V. PantalonMarek C. Chawarski;  Declan T. Barry;  Patrick G. O'Connor; Richard S. Schottenfeld

American Journal on Addictions, Volume 17, Issue 2 March 2008, pages 116 - 120

 

3! - Memantine enhances the inhibitory effects of naltrexone on ethanol consumption

Alexander KuzminCorresponding Author Contact Information, a, E-mail The Corresponding Author, Tove Stenbacka and Sture Liljequist

European Journal of Pharmacology. Volume 584, Issues 2-3, 28 April 2008, Pages 352-356

 

GRATIS 3 - Five-Factor Model personality profiles of drug users

Antonio Terracciano, Corinna E Lockenhoff, Rosa M Crum, O JOSEPH Bienvenu and Paul T Costa Jr.

BMC Psychiatry 2008, 8:22

 

3 - Neuroplasticity in brain reward circuitry following a history of ethanol dependence
Anita C. Hansson, Roberto Rimondini, Olga Neznanova, Wolfgang H. Sommer, Markus Heilig

European Journal of Neuroscience 2008; 27 (8), 1912–1922

 

3 - The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction

José Antonio López-Moreno, Gustavo González-Cuevas, Guillermo Moreno, Miguel Navarro
Addiction Biology. OnlineEarly Articles. April 2008

 

3 - The endocannabinoid system: emotion, learning and addiction

Fabrício A. Moreira, Beat Lutz
Addiction Biology. OnlineEarly Articles. April 2008

 

3 - Inhibitory Control Deficits in Childhood and Risk for Substance Use Disorders: A Review

Iliyan Ivanov;  Kurt P. Schulz;  Edythe D. London; Jeffrey H. Newcorn

The American Journal of Drug and Alcohol Abuse, Volume 34, Issue 3 May 2008, pages 239 - 258

 

3! - Smoking tobacco along with marijuana increases symptoms of cannabis dependence

Geoffrey L. Reama, Corresponding Author Contact Information, E-mail The Corresponding Author, Ellen Benoitb, Bruce D. Johnsonb and Eloise Dunlap

Drug and Alcohol Dependence. Volume 95, Issue 3, 1 June 2008, Pages 199-208

 

3 - Journey through the K-hole: Phenomenological aspects of ketamine use

L. MuetzelfeldtCorresponding Author Contact Information, a, E-mail The Corresponding Author, S.K. Kamboja, H. Reesa, J. Taylora, C.J.A. Morgana and H.V. Curran

Drug and Alcohol Dependence. Volume 95, Issue 3, 1 June 2008, Pages 219-229

 

3 - Clinical Pharmacology of Nicotine: Implications for Understanding, Preventing, and Treating Tobacco Addiction

NL Benowitz

Clinical Pharmacology & Therapeutics (2008); 83, 4, 531–541

 

5 - Human Abuse Liability of the Smoking Cessation Drug Varenicline in Smokers and Nonsmokers

SL McColl, AH Burstein, KR Reeves, CB Billing Jr, M Stolar and EM Sellers

Clinical Pharmacology & Therapeutics (2008); 83, 4, 607–614

 

3 - α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking

Berrettini, X Yuan, F Tozzi, K Song, C Francks, H Chilcoat, D Waterworth, P Muglia and V Mooser

Molecular Psychiatry (2008) 13, 368–373

 

3 - Genotype patterns that contribute to increased risk for or protection from developing heroin addiction

D A Nielsen, F Ji, V Yuferov, A Ho, A Chen, O Levran, J Ott and M J Kreek

Molecular Psychiatry (2008) 13, 417–428

 

3! - Prenatal Exposure to Maternal Cigarette Smoking and the Adolescent Cerebral Cortex

Roberto Toro, Gabriel Leonard, Jacqueline V Lerner, Richard M Lerner, Michel Perron, G Bruce Pike, Louis Richer, Suzanne Veillette, Zdenka Pausova and Tomás Paus

Neuropsychopharmacology (2008) 33, 1019–1027

 

5 - Bupropion for the Treatment of Methamphetamine Dependence

Ahmed M Elkashef, Richard A Rawson, Ann L Anderson, Shou-Hua Li, Tyson Holmes, Edwina V Smith, Nora Chiang, Roberta Kahn, Frank Vocci, Walter Ling, Valerie J Pearce, Michael McCann, Jan Campbell, Charles Gorodetzky, William Haning, Barry Carlton, Joseph Mawhinney and Dennis Weis

Neuropsychopharmacology (2008) 33, 1162–1170

 

5 - Abuse Liability of Prescription Opioids Compared to Heroin in Morphine-Maintained Heroin Abusers

Sandra D Comer, Maria A Sullivan, Robert A Whittington, Suzanne K Vosburg and William J Kowalczyk

Neuropsychopharmacology (2008) 33, 1179–1191

 

3 - Dissociation of the Neurochemical and Behavioral Toxicology of MDMA ('Ecstasy') by Citalopram

Brian J Piper, Joseph B Fraiman, Cullen B Owens, Syed F Ali and Jerrold S Meyer

Neuropsychopharmacology (2008) 33, 1192–1205

 

GRATIS 3 - Diagnosis and management of alcohol use disorders

Andrew J R Parker, E Jane Marshall, David M Ball

BMJ  2008;336:496-501 (1 March)

.

Regresar a RESÚMENES ABRIL 2008

.

© 1999-2008 Jorge M Tamayo, MD, BMSS

Creada en Enero 1999

Declaración: El contenido de esta página web está basado en las revisiones de la literatura realizadas por el autor y las colaboraciones enviadas por los lectores. Este sitio de Internet está dirijido únicamente a profesionales de la salud en Iberoamérica. Si usted es residente de Estados Unidos de América o Europa, debe tener en cuenta que los contenidos no han sido escogidos con base en información aprobada por la FDA o la EMEA.